Use of cryopreserved bone marrow in unrelated allogeneic transplantation

• Published in: Bone marrow transplantation (Basingstoke) Vol. 17; no. 2; p. 197
• Main Authors: Stockschläder, M, Krüger, W, tom Dieck, A, Horstmann, M, Altnöder, M, Löliger, C, Fiedler, W, Hoffknecht, M, Erttmann, R, Zander, A
• Format: Journal Article
• Language: English
• Published: England 01-02-1996
• Subjects: Adolescent; Adult; Aspergillosis - mortality; Bone Marrow; Bone Marrow Transplantation - adverse effects; Child, Preschool; Cryopreservation; Female; Graft Survival; Graft vs Host Disease - etiology; Graft vs Host Disease - mortality; Graft vs Host Disease - prevention & control; Humans; Infant; Leukocyte Count; Male; Middle Aged; Multiple Organ Failure - mortality; Neutrophils; Retrospective Studies; Time Factors; Tissue Preservation - methods; Treatment Outcome
• ISSN: 0268-3369

Cryopreservation of donor bone marrow can facilitate scheduling allogeneic bone marrow transplantation (BMT) by affording independence of a preset time for donation. Previously, we and others have shown the feasibility of using cryopreserved related allogeneic bone marrow. Here, we report the results of the first 10 patients receiving cryopreserved unrelated bone marrow between 1992 and 1995. All evaluable patients (n = 9) engrafted. Time to reach an absolute neutrophil count (ANC) >0.2 x 10(9)/1 and ANC >0.5 x 10(9)/l was 21.4 +/- 9.1 days and 22.6 +/- 9.2 days, respectively. The incidence of acute GVHD > or = grade II and chronic GVHD was 75 and 20%, respectively. Five of nine evaluable patients were alive 100 days post-transplantation. We conclude that cryopreserved unrelated donor bone marrow may be used for allogeneic transplantation.